NCT04196868 (METorMET²) is a Phase 2 clinical trial of Metformin treatment in Arthritis, Rheumatoid, sponsored by University Hospital, Bordeaux.

Who is sponsoring NCT04196868?

NCT04196868 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT04196868?

Interventions in NCT04196868: Metformin treatment, Placebo, Methotrexate treatment.

What condition does NCT04196868 study?

NCT04196868 studies Arthritis, Rheumatoid.

Is NCT04196868 still recruiting?

NCT04196868 is currently active, enrolled. Last updated 30 January 2026.

Last reviewed 2026-01-30 · How we verify

NCT04196868: METorMET²

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients

Active, enrolled Phase 2 Last updated 30 January 2026

What this trial tests

Phase 2 trial testing Metformin treatment in Arthritis, Rheumatoid in 128 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

3 December 2020

Primary endpoint
19 December 2024

1 June 2026

Quick facts

Lead sponsor	University Hospital, Bordeaux
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	128
Start date	3 December 2020
Primary completion	19 December 2024
Estimated completion	1 June 2026
Sites	12 locations across France

Drugs / interventions tested

Metformin treatment — full drug profile →
Placebo
Methotrexate treatment — full drug profile →

Conditions studied

Arthritis, Rheumatoid — all drugs for Arthritis, Rheumatoid →

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, any sex, with Arthritis, Rheumatoid. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change of level of RA activity according to Disease Activity score on 28 joints (DAS28-ESR)
Time frame: At baseline (Day 0) and 6 months after baseline

Sponsor's own description

Methotrexate (MTX) is the anchor drug for patients with rheumatoid arthritis (RA). Despite its marked efficacy and acceptable side effect profile, about 1/3 of patients failed to reach RA remission. Metformin is the first-line therapy for type 2 diabetes. Its antioxidative and anti-inflammatory properties make it a good candidate for the treatment of inflammatory diseases such as rheumatoid arthritis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Metformin treatment

Trials testing the same drug.

NCT06762041 — Effects of Metformin on Androgens and Other Steroid Hormones in Affected Subjects With Autism · not yet recruiting
NCT05838573 — Metformin Treatment on Cognitive Impairment of Schizophrenia · Phase 3 · recruiting
NCT07302932 — Metformin and Molecular Aging in Prediabetes · NA · completed
NCT03329651 — The Interaction Between Metformin and Acute Exercise · NA · completed
NCT03316690 — The Interaction Between Metformin and Physical Training · NA · completed

Other recruiting trials for Arthritis, Rheumatoid

Currently open trials in the same condition.

NCT07176390 — A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) · Phase 2 · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT06528431 — Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study · Phase 4 · recruiting
NCT06492200 — Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid Arthritis · NA · recruiting
NCT06246123 — A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants · recruiting

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04196868 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 30 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04196868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing